Scholarlink

Background <p>Sulfonylureas constitute the standard therapy for patients with HNF1A-MODY (maturity-onset diabetes of the young) but are characterized by an increased risk of hypoglycemia. While SGLT2 inhibitors (SGLT2i) may potentially represent a useful therapeutic option, data from the literature are scant.</p> Case presentation <p>We report the case of a young woman affected by HNF1A-MODY who was successfully and safely treated with an SGLT2i in addition to sulfonylurea. After SGLT2i initiation, an improvement in the patient’s glycemic control was observed and was maintained over time. No adverse effects were noted and, in particular, no increase in ketonemia or ketonuria occurred.</p> Conclusions <p>The use of SGLT2i under controlled circumstances may represent a useful therapeutic option in patients with HNF1A-MODY.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of SGLT2 inhibitors in the treatment of maturity-onset diabetes of the young (MODY): a case report and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月4日

查看全文
  • Michelle Bombonato,
  • Guglielmo Beccuti,
  • Andrea Benso,
  • Beatrice Giannone,
  • Silvana Bertaina,
  • Fabio Broglio,
  • Fabio Bioletto

摘要

Background

Sulfonylureas constitute the standard therapy for patients with HNF1A-MODY (maturity-onset diabetes of the young) but are characterized by an increased risk of hypoglycemia. While SGLT2 inhibitors (SGLT2i) may potentially represent a useful therapeutic option, data from the literature are scant.

Case presentation

We report the case of a young woman affected by HNF1A-MODY who was successfully and safely treated with an SGLT2i in addition to sulfonylurea. After SGLT2i initiation, an improvement in the patient’s glycemic control was observed and was maintained over time. No adverse effects were noted and, in particular, no increase in ketonemia or ketonuria occurred.

Conclusions

The use of SGLT2i under controlled circumstances may represent a useful therapeutic option in patients with HNF1A-MODY.